Events

Transparency is important to us, and we share our findings with the scientific community. We have presented data at numerous national and international medical meetings in order to disseminate our findings.

Dr Massimo Cristofanilli, MD Joins Datar Cancer Genetics as Strategic Advisor

Datar Cancer Genetics (DCG), a global leader in non-invasive cancer diagnostics, announces Dr. Massimo Cristofanilli as Strategic Advisor, reinforcing its commitment to advancing early cancer detection and precision treatment.

KNOW MORE

Datar Cancer Genetics Unveils Next Generation Multi-Analyte, AI-Powered Decision Support Platform for Personalised Treatment of Difficult-to-Treat Cancers

Datar Cancer Genetics (DCG) has launched Exacta AI, a next generation multi-analyte AI-driven platform providing optimised treatment options for cancer patients who have exhausted the standard options.

KNOW MORE

Datar Cancer Genetics to Provide Groundbreaking Video-Enhanced Results of In-Vitro Chemotherapy Effectiveness Tests for Cancer Patients

Datar Cancer Genetics (DCG) has launched a revolutionary video-reporting service for in-vitro chemosensitivity testing, powered by AI-driven technology. This innovation provides oncologists with real-time visual evidence of chemotherapy drugs' effectiveness on a patient's tumor cells, derived from tissue biopsies or blood.

KNOW MORE

Datar Cancer Genetics Introduces Revolutionary Tumour-Agnostic + Informed Blood Test for Residual Disease Monitoring

The Target-MRD blood test uses a combination of tumour-informed and tumour-agnostic molecular features for personalised, accurate and more effective monitoring of molecular residual disease.

KNOW MORE

Emerging Therapies Explained: Blood Test for Brain Tumours

BRAIN TUMOUR RESEARCH

KNOW MORE

Datar Cancer Genetics and Cromwell Hospital's Second Opinion Service

Cromwell Hospital, a world-leading private hospital in London, is working with Datar Cancer Genetics as a trusted second opinion partner.

KNOW MORE

Sir Ian Botham: I've never been in the dressing room with any form of racism

Lord Ian Botham talks not just about racism but also the value of early cancer detection as he recently took the multi-cancer detection solution Trucheck Intelli.

KNOW MORE

US FDA Grants Breakthrough Designation for Blood Test to Help Diagnose Inaccessible Brain Tumors

Datar Cancer Genetics now has three Breakthrough Designations granted by the USFDA, including liquid biopsies for breast and prostate cancer detection.

KNOW MORE

Blood Test Which Spots 'Nearly Every Case of Cancer' Before it Spreads, Will Improve Early Treatment

The Trucheck Intelli blood test can identify 70 types of cancer, with the company hoping it can be rolled out across the NHS

KNOW MORE

'Game Changer' Blood Test Detects Breast Cancer

'Game-changer' blood test detects breast cancer earlier than X-rays, study shows.

KNOW MORE

Landmark Liquid Biopsy Study

Landmark Liquid Biopsy Study Shows Accurate Detection of Early-Stage Breast Cancer.

KNOW MORE

The London Clinic

Datar Cancer Genetics enters into partnership with The London Clinic to offer enhanced cancer testing services

KNOW MORE

FDA - Prostate Cancer

Datar's TriNetra-Prostate Blood Test Gets FDA Breakthrough Designation.

KNOW MORE

South Africa

Groundbreaking high-sensitivity cancer screening test arriving in SA ahead of World Cancer Day.

KNOW MORE

Kuwait

Virtus Group announces partnership with Datar Cancer Genetics for personalised precision oncology solutions in Kuwait.

KNOW MORE

FDA - Breast Cancer

US FDA Grants Breakthrough Designation for Early-Stage Breast Cancer Detection Blood Test Developed by Datar Cancer Genetics.

KNOW MORE

The Healthcare Technology Report

The Top 25 Women Leaders in Biotechnology of 2021 (Swati Deshpande - Datar Cancer Genetics)

KNOW MORE

NICE - UK

UK - National Institute for Health and Care Excellence (NICE) issues MedTech Innovation Briefing on 'Trublood-Prostate' for Precision Non-Invasive Prostate Cancer Diagnosis Described by Experts as a 'Game Changer'.

KNOW MORE
Got An Enquiry?
Contact Us.